Abstract
Get full access to this article
View all access options for this article.
References
1.
Silverman
E.
A bill would prevent drug makers from frustrating generic rivals. June 23, 2015 . Wall Street Journal Web site, http://blogs.wsj.com/pharmalot/2015/06/23/a-bill-would-prevent-drug-makers-from-frustrating-generic-rivals/. Accessed November 3, 2015.
2.Letter to Congressmen Stivers and Welch. Generic Pharmaceutical Association Web site. http://www.gphaonline.org/media/cms/2015_Group_Letter_of_Support_for_FAST_Generics.pdf. Accessed November 3, 2015.
3.FDA basics webinar: A brief overview of Risk Evaluation and Mitigation Strategies (REMS). US Food and Drug Administration Web site. http://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm. Accessed November 3, 2015.
4.
Brill
A.
Lost prescription drug savings from use of REMS programs to delay generic market entry. July 2014 . http://www.gphaonline.org/media/cms/REMS_StudyfinalJuly2014.pdf. Accessed November 3. 2015.
5.Fair Access for Safe and Timely Generics Act of 2015. HR 2841. June 18, 2015 . https://www.congress.gov/bill/114th-congress/house-bill/2841/text. Accessed November 3, 2015.
6.
Karst
K.R.
FAST Generics Act would amend the FDC Act to address REMS/restricted access programs and biostudy sample availability . September 18, 2014 . FDA Law Blog Web site, http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/09/fast-generics-act-would-amend-the-fdc-act-to-address-remsrestricted-access-proRrams-and-biostudv-sam.html. Accessed November 3, 2015.
7.
Gilchrist
A.
FAST Generics Act reintroduced in Congress. September 16, 2015 . Pharmacy Times Web site, http://www.pharmacytimes.com/publications/issue/2015/septem-ber2015/fast-generics-act-reintroduced-in-congress. Accessed November 3, 2015.